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OBJECTIVES The aim of this study was to investigate the influence of prehospital administration of aspirin
and heparin on the initial patency of the infarct-related artery (IRA) in patients with acute
myocardial infarction (MI).
BACKGROUND Prehospital diagnosis of acute MI facilitates early pharmacologic intervention on the way to
the catheterization laboratory for primary angioplasty.
METHODS We studied the angiographic data and 30-day clinical outcome of 1,702 patients treated with
primary angioplasty; 860 received aspirin and heparin before transportation to our hospital
and 842 received aspirin and heparin in our hospital.
RESULTS The Thrombolysis In Myocardial Infarction (TIMI) 2 or 3 flow in the IRA was higher in the
prehospital treated group (31% vs. 20%, relative risk 0.65, 95% confidence interval 0.55 to
0.78, p  0.001). Patients with TIMI 2 or 3 flow on the initial angiogram had a higher
angioplasty success rate (94% vs. 89%, p  0.001), a smaller enzymatic infarct size, a higher
left ventricular ejection fraction and a lower 30-day mortality (1.6% vs. 3.4%, p  0.04).
CONCLUSIONS Prehospital administration of aspirin and heparin results in a higher initial patency of the IRA
in patients with acute MI. (J Am Coll Cardiol 2002;39:1733–7) © 2002 by the American
College of Cardiology Foundation
Early coronary reperfusion is the primary goal of the initial
treatment for patients with acute ST segment elevation
myocardial infarction (MI). The delay between symptom
onset and effective myocardial reperfusion is one of the
determinants of early and late clinical outcome. Primary
angioplasty is a highly effective reperfusion therapy, result-
ing in complete and sustained patency of the infarct-related
artery (IRA) in most patients (1–3). The total ischemic time
of patients with acute MI treated with primary angioplasty
is a combination of patient delay, response delay of the
primary care system, transportation delay and the time
needed to establish reperfusion in the catheterization labo-
ratory (4). Adjunctive therapy given after diagnosis but
before angioplasty may induce reperfusion, thereby limiting
myocardial injury. Several types of drugs have been studied
for this specific purpose with variable results (5–9).
In a steadily increasing proportion of patients, the diag-
nosis of ST elevation MI is accomplished out-of-hospital,
before transportation, either by general practitioners or by
ambulance personnel with 12-lead electrocardiography.
This allows very early pretreatment with advantages analo-
gous to prehospital thrombolysis compared with hospital-
based thrombolysis (4). Therefore, we studied the initial
coronary angiograms of consecutive patients who had re-
ceived aspirin and heparin before reaching the hospital and
compared these findings with a consecutive group of pa-
tients who had received aspirin and heparin after arrival in
our hospital, all on the way to our catheterization laboratory
for primary angioplasty.
METHODS
Patients with acute MI presenting within 6 h after symptom
onset were included. The protocol was approved by our
institutional review board. Electrocardiographic criteria
were ST segment elevation of 1 mm in two or more
contiguous leads. The diagnosis of acute MI and the
indication for primary angioplasty was established in 860
patients at the patient’s home by the ambulance crew or at
the emergency department of one of the 11 community
hospitals who refer patients to our hospital for primary
angioplasty. These patients received aspirin (500 mg intra-
venously) and heparin (5,000 IU intravenously) before
transportation to our hospital. During the same period, the
diagnosis of acute MI and the indication for primary
angioplasty was established in 842 patients in the emergency
room of our hospital. These patients received aspirin and
heparin intravenously in the emergency room and were
transported immediately to the catheterization laboratory.
None of these patients received fibrinolytic therapy or
glycoprotein IIb/IIIa blockers before angiography.
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Data collection. Demographic and clinical data were re-
corded at baseline. The primary end point was the patency
of the IRA at diagnostic angiography. All angiograms were
reviewed by two cardiologists, blinded for treatment alloca-
tion and clinical data. At discharge, left ventricular ejection
fraction (LVEF) was measured with a radionuclide tech-
nique, as previously described (2). All major cardiovascular
events during hospital admission were documented. Major
bleeding was defined as blood loss, requiring blood trans-
fusion. Enzymatic infarct size was determined by measure-
ments of lactate dehydrogenase as reference enzyme. Cu-
mulative enzyme release was calculated from serial
measurements up to 48 h after symptom onset. From these
measurements, an area under the curve was calculated from
at least five measurements (enzymatic infarct size from serial
measurements of lactate dehydrogenase [LDHQ48]). Fur-
ther details of this method have been described previously
(10,11). Complete clinical data were available of all 1,702
patients; LDHQ48 was determined in 890 patients; LVEF
was determined in 1,086 patients.
Data analysis. Continuous data are summarized as means
and SD. Variables were compared using the Fisher exact test
or chi-square test for categorical data. Analysis of variance
was utilized for normally distributed continuous variables. A
nonparametric (Kruskal-Wallis) test was used to compare
continuous variables when the data were not normally
distributed.
RESULTS
A total of 1,702 patients were included, of whom 860
received aspirin and heparin before transfer to our hospital
and 842 received aspirin and heparin after arrival in our
hospital. Baseline characteristics are shown in Table 1. With
respect to gender, Killip class, previous MI, diabetes, mul-
tivessel disease and ischemic time, there were no differences
between the two groups. The patients in the prehospital
aspirin and heparin group were slightly younger and pre-
sented more often with an anterior MI location. The time
interval from aspirin and heparin administration to angiog-
raphy in the prehospital group was measured in 117 patients
and was 81  43 min, compared with a time interval from
aspirin and heparin administration to angiography in the
in-hospital group of 26  39 min (p  0.001). The
prevalence of use of aspirin before their MI was 8% in the
prehospital group compared with 9% (p  NS) in the
in-hospital group with doses ranging from 38 to 100 mg/day.
In 263 of 860 patients (31%) in the prehospital aspirin and
heparin group, Thrombolysis In Myocardial Infarction
(TIMI) flow grade 2 or 3 was observed compared with 168
of 842 patients (20%) in the group who received aspirin and
heparin after arrival in our hospital (relative risk 0.65, 95%
confidence interval 0.55 to 0.78, p  0.001). The TIMI 3
flow was observed in 141 of 860 (17%) in the prehospital
group compared with 83 of 842 (10%) in the in-hospital
group (relative risk 0.60, 95% confidence interval 0.47 to
0.78, p  0.001). This effect of prehospital treatment was
present in almost all subgroups of patients (Table 2).
Clinical outcome. Primary angioplasty was successful
(TIMI flow grade 3 and residual stenosis 50%) in the
prehospital group in 92% of patients compared with 90% in
patients of the hospital group. There were four strokes
(0.2%), one in the prehospital group (0.1%) and three in the
in-hospital group (0.4%). Bleeding necessitating a blood
transfusion occurred in 43 of 860 (5%) patients in the
prehospital group and 59 of 842 (7%) patients in the
in-hospital group. In the prehospital group, 26 of 860
(3.0%) had died at 30 days compared with 24 of 842 (2.9%)
of patients in the in-hospital group. Death and nonfatal
reinfarction occurred in 34 (4%) prehospital patients and 32
(3.8%) in-hospital patients. Clinical outcome variables are
given in Table 3.
The presence or absence of TIMI 2 or 3 flow on the
initial diagnostic angiogram was a major determinant of
clinical outcome. Patients with initial TIMI 2 or 3 flow in
the IRA more often had TIMI 3 flow after the angioplasty
procedure and had a smaller LDHQ48. A better LVEF and
a lower 30-day mortality was observed in anterior MI.
Clinical outcome variables according to TIMI flow on the
initial diagnostic angiogram are given in Table 4.
DISCUSSION
The prehospital administration of aspirin and heparin is a
simple, inexpensive and widely applicable treatment option
in patients with suspected or confirmed acute MI. We
studied the value of prehospital aspirin and heparin in a
large cohort of patients on the way to the catheterization
laboratory for primary angioplasty of the IRA, but this
strategy can also be used in combination with other phar-
Abbreviations and Acronyms
HEAP  Heparin in Early Patency trial
IRA  infarct-related artery
LDHQ48  enzymatic infarct size from serial
measurements of lactate dehydrogenase
LVEF  left ventricular ejection fraction
MI  myocardial infarction
TIMI  Thrombolysis In Myocardial Infarction
Table 1. Baseline Characteristics
Prehospital Heparin
and Aspirin
No Prehospital
Heparin and Aspirin
p
Value
Age, yrs 59  11 61  12 0.01
Men 81% 79% 0.24
Anterior MI 65% 36% 0.001
Killip class 11 11% 11% 0.95
Previous MI 11% 12% 0.54
Diabetes 8.5% 8.2% 0.60
Multivessel disease 53% 54% 0.57
Ischemic time 3 h 54% 51% 0.21
Ischemic time  time between symptom onset and first balloon inflation; MI 
myocardial infarction.
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macologic therapies, when thrombolytic therapy is contra-
indicated and angioplasty is not available.
Previous studies with heparin. Previous observations have
shown conflicting results as to the effects of heparin on early
patency of the IRA (6,7,12,13). As an adjunct to alteplase,
heparin has been shown to result in a higher patency rate in
a trial of the European Cooperative study group (14). In the
Global Utilization of Streptokinase and t-PA for Occluded
Coronary Arteries trial, heparin was not effective in combi-
nation with streptokinase (15,16). In an observational study,
heparin was not associated with an improved 30-day mor-
tality rate (13). The effect of high-dose intravenous heparin
on initial patency was promising in a pilot trial (6), but the
subsequent randomized Heparin in Early Patency (HEAP)
trial did not confirm a benefit of high-dose heparin on early
patency (7). However, a large majority of the patients in the
HEAP trial received heparin after hospital admission and,
therefore, the time available for heparin to induce reperfu-
sion was limited. There are several potential reasons why
prehospital intravenous heparin may be more effective in
this setting. For instance, pharmacologic treatment during
the first 1 h or 2 h may be more effective due to a less
organized occluding thrombus. As heparin had its anti-
thrombin effects within minutes after administration, the
pretreated patients had been anticoagulated longer com-
pared with the patients who received heparin in our emer-
gency room. Early restoration of flow may reduce the
ischemic insult and limit reperfusion injury.
Aspirin and other pharmacologic interventions. The
beneficial effects of aspirin in patients with acute MI have
been established in the International Study of Infarct
Survival-2 (17). Whether this beneficial effect may, in part,
be due to a higher early patency rate has not been studied.
In the present study, prehospital administration of heparin
Table 2. TIMI 2 and 3 Flow on the Initial Coronary Angiogram
n
Prehospital Heparin
and Aspirin (%)
No Prehospital
Heparin and
Aspirin (%) RR (95% CI) p Value
All patients 1,702 31 20 0.65 (0.55–0.78) 0.001
Age 60 yrs 868 32 22 0.69 (0.55–0.86) 0.001
Age 60 yrs 834 32 21 0.65 (0.51–0.82) 0.001
Men 1,362 31 20 0.66 (0.54–0.79) 0.001
Women 340 36 24 0.67 (0.48–0.94) 0.02
Anterior MI 854 32 24 0.76 (0.61–0.95) 0.01
No anterior MI 848 30 19 0.80 (0.69–0.92) 0.001
Killip class 2 189 25 18 0.72 (0.41–1.24) 0.23
Killip class 1 1,513 32 22 0.66 (0.56–0.79) 0.001
Ischemic time 3 h 815 32 21 0.66 (0.52–0.83) 0.001
Ischemic time 3 h 887 31 21 0.68 (0.54–0.85) 0.001
Single-vessel disease 791 35 24 0.75 (0.62–0.89) 0.001
Multivessel disease 911 29 19 0.75 (0.63–0.89) 0.001
Diabetes 139 34 31 0.91 (0.56–1.48) 0.71
No diabetes 1,563 31 20 0.65 (0.55–0.78) 0.001
CI  confidence interval; MI  myocardial infarction; RR  relative risk; TIMI  Thrombolysis In Myocardial Infarction.
Table 3. Clinical Outcome Variables of the Two Groups
Prehospital
Heparin and
Aspirin
(n  860)
No Prehospital
Heparin and
Aspirin
(n  842)
p
Value
Angioplasty success 92% 90% 0.13
Infarct size (LDHQ48)
Anterior MI 1,421  1,187 1,691  1,273 0.17
Nonanterior MI 705  823 849  797 0.29
LVEF
Anterior MI 43  11 37  12 0.03
Nonanterior MI 50  12 47  12 0.22
30-day mortality
All patients 3.0 2.9 0.65
Anterior MI 3.6 4.4 0.27
Nonanterior MI 2.3 2.0 0.14
Angioplasty success is defined as Thrombolysis In Myocardial Infarction flow grade
3 and a residual stenosis 50% after the procedure. Infarct size was calculated in 890
patients, from serial measurements of lactate dehydrogenase up to 48 h after symptom
onset.
LDHQ48  enzymatic infarct size from serial measurements of lactate dehydro-
genase; LVEF  left ventricular ejection fraction measured in 1,086 patients with a
radionuclide technique; MI  myocardial infarction.
Table 4. Clinical Outcome Variables According to Initial
TIMI Flow
Initial TIMI Flow
p Value0/1 (n  1,271) 2/3 (n  431)
Angioplasty success 89% 94% 0.01
Infarct size (LDHQ48)
Anterior MI 1,787  1,627 1,178  1,055 0.05
Nonanterior MI 1,031  998 661  701 0.05
LVEF
Anterior MI 39  12 47  11 0.001
Nonanterior MI 48  11 50  12 0.09
30-day mortality
All patients 3.4 1.6 0.04
Anterior MI 4.9 1.2 0.01
Nonanterior MI 2.0 2.1 0.78
Angioplasty success is defined as Thrombolysis In Myocardial Infarction (TIMI) flow
grade 3 and a residual stenosis 50% after the procedure. Infarct size was calculated
in 890 patients, from serial measurements of lactate dehydrogenase up to 48 h after
symptom onset.
LDHQ48  enzymatic infarct size from serial measurements of lactate dehydro-
genase; LVEF  left ventricular ejection fraction measured in 1,086 patients with a
radionuclide technique; MI  myocardial infarction.
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in combination with aspirin enhanced early patency, but the
relative importance of these two components is unknown. A
small group of patients (8% to 9%) was using aspirin before
their MI, a group too small to analyze separately. Whether
the effects of pretreatment with intravenous aspirin and
heparin are different in patients already using aspirin is
unknown. However, our results did not change when we
excluded these patients from our analysis. Compared with
other pharmacologic interventions such as low dose throm-
bolytic drugs (5) or glycoprotein IIb/IIIa receptor blockers
(8,9), the effect of prehospital administration of aspirin and
heparin may seem modest. Aspirin and heparin result in one
additional open IRA on the initial coronary angiogram for
every 10 patients treated compared with 1 of 6 patients
treated with low-dose lytics (5) or abciximab (8), but aspirin
and heparin are comparatively safe and inexpensive.
Study limitations. Treatment (prehospital vs. in-hospital
heparin and aspirin) was not allocated by randomization but
dependent on the routing of the patient on the way to our
catheterization laboratory. Patients diagnosed with acute
MI in an emergency room of a referring hospital (4,18) or at
home after arrival of an ambulance with 12-lead electrocar-
diography had prehospital treatment with heparin and
aspirin, whereas the other group received these two drugs
after arrival in our hospital. The slight difference in age and,
in particular, the higher rate of anterior MI location is due
to selection bias of referring physicians and ambulance
personnel. They refer, preferentially, patients for primary
angioplasty with large anterior wall MI (4,18). Therefore,
we analyzed the impact of the baseline characteristics on the
main results of our study (Table 2). There is no interaction
between treatment effect and age, gender, MI location,
ischemic time and multivessel disease. With regard to Killip
class 2 and diabetes, our results are not conclusive due to
the limited number of patients with this characteristic, but
this does not interfere with the comparison of the two
groups.
Treatment allocation was not blinded, but this will not
have influenced our findings, as the angiograms were
reviewed without knowledge of allocation or clinical data.
We did not find a significant difference in mortality between
the prehospital and the in-hospital group. This is probably
due to the fact that most patients left the catheterization
laboratory with a patent IRA and, as a consequence,
mortality in this 1,702 patient cohort was very low (3%).
Nevertheless, when we analyzed clinical outcome in patients
with TIMI 2 or 3 flow on the initial angiogram and
compared that to patients with an initially occluded coro-
nary artery, the benefits of early patency of the IRA are
confirmed (Table 4) (5,19,20).
Conclusions. Prehospital compared with in-hospital ad-
ministration of aspirin and heparin in patients with acute
MI results in a higher rate of early patency of the IRA.
Patients with antegrade flow in the IRA on the initial
angiogram have a better clinical outcome compared with
patients with an occluded coronary artery.
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